Corrected genomic and complementary DNA (cDNA) ratios for rs2070106. Comparison between the observed corrected genomic ratios and the corrected cDNA ratios assayed for 2′,3′-cyclic nucleotide 3′-phosphodiesterase (n = 25). Data are expressed as the mean of the ratio of A:G for 2 measurements of each genomic DNA sample and 4 measurements of each cDNA sample.
Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A, Haroutunian V, Buxbaum JD, Owen MJ, O’Donovan MC. Convergent Evidence for 2′,3′-Cyclic Nucleotide 3′-Phosphodiesterase as a Possible Susceptibility Gene for Schizophrenia. Arch Gen Psychiatry. 2006;63(1):18–24. doi:10.1001/archpsyc.63.1.18
Convergent data make 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) a candidate gene for schizophrenia. Reduced expression has been reported in the schizophrenic brain. The CNP gene maps to a region to which we have reported linkage to schizophrenia. Mice in which the CNP gene has been knocked out display central nervous system pathological characteristics reminiscent of some features observed in schizophrenia. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase is used as a marker of myelin-forming cells and is detectable in cells of oligodendrocyte lineage throughout life. Because CNP is thought to be important for oligodendrocyte function, altered expression has been interpreted as supportive of the hypothesis that altered oligodendrocyte function may be an etiological factor in schizophrenia. However, it is unclear whether the observed changes in the schizophrenic brain are primary or secondary.
To determine if CNP expression is influenced by DNA polymorphisms and to verify if these polymorphisms are associated with schizophrenia.
Allele-specific messenger RNA expression assay and genetic association studies.
Unrelated subjects were ascertained from secondary psychiatric inpatient and outpatient services.
We used brain tissue from 60 anonymous individuals with no known psychiatric disorder; a case-control sample of 708 white individuals from the United Kingdom meeting DSM-IV criteria for schizophrenia matched for age, sex, and ethnicity to 711 blood donor controls; and a pedigree with DNA from 6 affected siblings and 1 parent, showing evidence for linkage to CNP.
Main Outcome Measures
Association between allele and gene expression. Association between allele and schizophrenia.
The exonic single nucleotide polymorphism rs2070106 was associated with CNP expression (P<.001). Compatible with underexpression of CNP messenger RNA in schizophrenia, the lower-expressing A allele was significantly associated with schizophrenia (P = .04) in the case-control sample. All affected individuals in the linked pedigree were homozygous for the lower-expression allele, providing independent support for the association (P = .03).
Our data support the hypothesis that reduced CNP expression in the schizophrenic brain is relevant to disease etiology and therefore provide support for the general hypothesis that altered oligodendrocyte function is an etiological factor in schizophrenia.
Methods for testing genes using association designs in general offer more power to detect small effects than methods based on linkage, but until genomewide association scans become economically realistic, such analyses are dependent on prior functional and/or positional support for a disease locus. Unfortunately, our current knowledge of the functional pathological characteristics of schizophrenia so far only provides broad clues about the pathological mechanisms that might be involved, and therefore, it is difficult to define a group of candidate genes small enough to be comprehensively studied.
Global surveys of messenger RNA (mRNA) expression levels offer an alternative approach to linkage for selecting candidate genes and/or pathophysiological pathways for a disease in the absence of a prior hypothesis linking the function of that gene or pathway to the disease etiology.1 Although the large number of transcripts to be examined, as well as the numerous potential sources of experimental and sampling variance that accompany the use of complex tissues obtained post mortem, poses significant analytic and design problems, recent studies suggest that robust and etiologically relevant changes in gene expression can be detected even in tissues as complex as the human postmortem brain. Examples include the identification of altered expression of the neuregulin receptor erbB3 in the schizophrenic brain,2,3 a finding whose relevance is supported by the evidence implicating variation in the gene encoding its ligand, neuregulin 1, in susceptibility to schizophrenia.4 Others include the identification of the G protein receptor kinase 3 gene as a candidate gene for bipolar disorder5 and the regulator of G-protein signaling 4 as a candidate gene for schizophrenia,6 findings that have received supportive evidence from follow-up genetic studies.7,8 In the cases of regulator of G-protein signaling 4 and the G protein receptor kinase 3 gene, each was selected for genetic analysis because, as well as displaying altered expression, each mapped to a putative region of linkage for the relevant disorder. Thus, each candidate gene was supported by data from 2 non−hypothesis based methods, an approach that has been termed convergent functional genomics.5
Recently, microarray studies have reported the down-regulation of genes related to oligodendrocyte function and myelination in the schizophrenic brain compared with control subjects.2,3,9 Among the mRNAs down-regulated was that encoded by the 2′,3′-cyclic nucleotide 3′-phosphodiesterase gene (CNP), a finding confirmed at the protein level by Flynn and colleagues.10 These observations are of interest because CNP maps to 17q21.2, a region of the genome in which we have recently observed genomewide significant evidence for linkage (logarithm odds score, 8.32; genomewide empirical P value ≤ .02) to schizophrenia in a single pedigree.11 Moreover, given evidence for altered myelination and oligodendrocyte function in schizophrenia,12CNP is also a plausible functional candidate gene.
2′,3′-Cyclic nucleotide 3′-phosphodiesterase is widely used as a marker protein of myelin-forming glial cells. In brain development, CNP is detectable in cells of oligodendrocyte lineage and is maintained in mature oligodendrocytes throughout life.13 2′,3′-Cyclic nucleotide 3′-phosphodiesterase is associated with noncompacted myelin regions, absent from compacted myelin, and also found in oligodendrocyte cytoplasm.10 Although the precise function of CNP in oligodendrocytes is unclear, recent evidence suggests that it interacts with mitochondria and cytoskeletal proteins and may act to promote microtubule assembly or act as a membrane anchor for tubulin.14 Intriguingly, a recent animal study showed that CNP-deficient mice display a reduction in overall brain size, enlarged ventricles, and corpus callosum atrophy, all of which are consistent with pathological features observed in schizophrenia.13
That altered CNP expression can be observed and replicated in small samples of cases and controls suggests a schizophrenia-related influence on CNP expression that is probably too large and homogeneous to attribute entirely to genetic variation at the CNP locus itself. If altered CNP expression is relevant to pathogenesis, it is probably as a final common pathway resulting from multiple trans-acting genetic and environmental risk factors. Alternatively, the replicated evidence for the association between altered CNP expression and schizophrenia in small samples might suggest that the former is a common consequence of the latter, for example, a result of its treatment.
In this study, we applied molecular genetic approaches in a bid to distinguish between the hypotheses mentioned earlier. The rationale underpinning our study was that if it is true that altered CNP expression influences schizophrenia susceptibility, any direct influences on CNP expression resulting from a cis-acting polymorphism at the CNP locus will have a similar effect, albeit probably with a small genetic effect size. Thus, we sought evidence that the expression of CNP is influenced by at least 1 cis-acting polymorphism using a highly quantitative allele-specific expression assay.15 Second, we sought direct and indirect evidence for association between CNP and schizophrenia in a large sample of schizophrenic cases and controls. Third, we examined the sequence of CNP in a family showing evidence for 17q linkage to schizophrenia for the presence of alleles that might represent rare alleles of large effect size. Fourth, we undertook de novo polymorphism discovery across the complete genomic sequence (including introns) of CNP and examined all variants for evidence of association with schizophrenia. The analyses presented show that CNP is indeed subject to cis-acting influences on gene expression, that an allele associated with lower CNP expression is also associated with schizophrenia, and that while all affected members of the pedigree showing evidence for linkage to schizophrenia were less identical by descent on 17q than suggested by our original linkage analysis, all were homozygous for the less common putative risk allele, a finding that is unlikely to occur simply by chance.
Our case-control sample consisted of 708 white subjects with schizophrenia from the United Kingdom and Ireland (487 men and 221 women), matched for age, sex and ethnicity to 711 blood donor controls (478 men and 233 women). All patients had a consensus diagnosis of schizophrenia according to DSM-IV criteria made by 2 independent raters following a semistructured interview by trained psychiatrists or psychologists using the Schedules for Clinical Assessment in Neuropsychiatry interview16 and review of case records. High levels of reliability (κ >0.8) were achieved between raters for diagnoses. All cases were screened to exclude substance-induced psychotic disorder or psychosis due to a general medical condition. The mean (SD) age at first psychiatric contact was 23.6 (7.7) years and the mean (SD) age at ascertainment was 41.8 (13.5) years. The blood donor controls were not specifically screened for psychiatric illness but individuals were not taking regular prescribed medications. In neither country are blood donors remunerated even for expenses, and as a result, blood donors are not enriched for substance abusers or indigents who may have relatively high rates of psychosis. Ethics committee approval was obtained in all regions where patients were recruited, and informed written consent was obtained from all participants. The pedigree showing evidence for linkage to 17q11 consisted of a single sibship of 6 individuals with DSM-IV schizophrenia (diagnosed as described earlier) from whom DNA was available. DNA was also available from 1 parent of unknown diagnostic status but who was believed to be unaffected.
Primers to amplify exons, promoters, flanking sequences, and introns were designed based on alignment of mRNA sequence (NM_033133) and the corresponding genomic sequence (NT_010755.14). Polymerase chain reaction amplification and mutation screening were performed using denaturing high-performance liquid chromatography and, where indicated, sequencing, using protocols we have described extensively.17,18
The sample for mutation screening consisted of 14 unrelated white subjects from the United Kingdom meeting DSM-IV criteria for schizophrenia, each of whom had at least 1 affected sibling. At a later stage, we also screened all available individuals from the linked pedigree.
The principle of the assay is that in heterozygous carriers of a cis-acting polymorphism that affects the transcription or stability of a species of mRNA, the quantity of mRNA originating from each gene copy will be unequal. The simplest method for distinguishing between mRNA molecules originating from each copy of a pair of autosomal genes is to use a polymorphism within the mRNA sequence as a copy-specific tag.15 It is then possible to apply quantitative methods of allele discrimination to mRNA samples originating from individuals who are known to be heterozygous for the marker polymorphism in order to measure relative copy expression.15 Factors that can influence the measured amount of total expression of a specific gene (eg, tissue preparation, mRNA quality, drug exposure, preagonal state, hormones, effects secondary to regulatory polymorphisms in other genes) will, in the absence of a cis-acting allele-specific interaction, influence the amount of mRNA originating from each chromosome equally and are therefore controlled for by this assay. While not allowing the measurement of total RNA abundance, the allelic expression assay does have the major advantage of allowing the detection of small polymorphic cis-acting influences even in the face of large trans-acting influences.
Postmortem brain tissue was derived from the frontal, parietal, or temporal cortex of 60 white, European, unrelated, anonymized human adults of whom 50 were from the United Kingdom (the Medical Research Council London Neurodegenerative Diseases Brain Bank, London, England) and 10 were from Sweden (Department of Clinical Neuroscience, Karolinska Institute, Stockholm). All were free from psychiatric or neurological disorder at the time of death. Genomic DNA and RNA were extracted from each individual tissue sample, with subsequent deoxyribonuclease treatment of RNA as described.15 Heterozygotes for the transcribed marker single-nucleotide polymorphism (SNP) were identified by genotyping genomic DNA from all subjects. Allelic expression was estimated as described by Bray et al.15,19 Briefly, deoxyribonuclease-treated RNA samples were subject to reverse-transcription polymerase chain reaction and primer extension with allele-specific dye-terminator incorporation using the SNaPshot kit (Applied Biosystems, Foster City, Calif), and the relative levels of the products representing each transcribed allele were measured on a capillary sequencer. Samples were assayed using primers based on single exonic sequence, capable of amplifying either genomic DNA or complementary DNA (cDNA). The cDNA samples were assayed alongside the corresponding heterozygote genomic DNA, which represents a perfect 1:1 ratio of the 2 alleles. The ratio obtained from genomic DNA thus provided a correction factor for any inequalities in the efficiency of allelic representation specific to each cDNA assay.20 Absence of genomic DNA in the RNA extracts was confirmed by including the RNA samples that had not been reverse transcribed. Analysis of heterozygous samples was performed as 2 separate experiments. In each experiment, 2 cDNA samples were assayed for each heterozygous individual (as 2 separate reverse-transcription reactions), alongside the corresponding genomic DNA sample.
Individual genotyping was performed using AcycloPrime reagents (PerkinElmer Life Science Products, Boston, Mass). Genotypes were scored blind to affection status, and each plate of samples contained a mixture of equal numbers of cases and controls.
The DNA pools from 691 of the cases and 710 of the controls were also genotyped using the SNaPshot primer extension (Applied Biosystems) protocol described by us in detail by Norton et al.21
A grid of SNPs (minimum density of 1 SNP every 5 kilobases [kb]) across CNP, spanning the genomic sequence from 4 kb 5′ to the transcription start site through to 1 kb 3′ to the end of transcription was identified from the CHIP bioinformatics database.22 A linkage disequilibrium (LD) approach was used to supplement our direct gene analyses because genetic variation altering expression may occur in genomic sequences whose locations are unpredictable with reference to the exonic sequence.
Contingency tables were used to test genotypes and alleles for association with schizophrenia and to calculate odds ratios. All analyses were 2-tailed. Power estimations were calculated using the Web-based program provided by the Department of Statistics, University of California, Los Angeles.23 The D′ and r2 estimates of LD were calculated using the Web program Haploview.24 Haplotype frequency analysis was performed using EH plus25 with a permutation test.26 A low-redundancy set of SNPs for haplotype analysis was selected using an entropy method developed in house (V.M., unpublished data, 2003). Entropy as a measure of haplotypic diversity is calculated as:
where fi is the frequency of the i-th haplotype, and k is the number of distinct haplotypes in the sample. The haplotype frequencies fi were obtained using the Expectation maximization-algorithm realized in the EH plus software.25,26 The basic principle of defining tag markers is that the larger the value of entropy, the more informative is the set of markers forming the haplotype. For m biallelic markers (eg, SNPs), the number of possible haplotypes is 2m. The full amount of information for these m markers is:
where fi are the m markers’ haplotype frequencies. Calculating entropies for each subset of these m markers and dividing them by Efull, we obtain the relative amount of information (values between 0 and 1) provided by a particular subset of markers compared with the full set of markers. By this method, optimal haplotype-tagging SNPs can be selected even in the absence of a clear haplotypic block structure. A similar approach is described in Ackerman et al.27 Entropy calculations were based on genotypes of all the markers in 96 unrelated control subjects. These individuals were not part of the matched control sample and are not included in the analysis.
Initial analysis of the CNP exonic sequence of 14 unrelated individuals with schizophrenia revealed 4 novel variants (−351 G>A, 4926 G>A, 7230 G>A, and 7284 G>A) and 2 variants already lodged in the CHIP bioinformatics database (rs4432296 and rs2070106). Single nucleotide polymorphism labeling is based on genomic sequence (NT_010755.14) and follows the labeling protocol suggested.28 Of these, 3 were exonic (rs2070106, 7230 G>A, and 7284 G>A), although none encode an amino-acid change. Pooled analysis revealed that rs2070106 had the highest minor allele frequency, and this SNP was subsequently selected as a marker for allelic expression analysis.
Of the 60 subjects for whom brain was available, 25 individuals were heterozygous for SNP rs2070106 and therefore informative for analysis. Allelic expression analysis of these individuals revealed that in each case, the A allele was expressed at a lower level than the G allele (Figure). The data points from each individual cDNA sample showed good reproducibility, with a mean coefficient of variation of 0.07. When data from all the individuals were combined, the A allele was significantly underexpressed (P<.001), a finding that was replicated in a repeat analysis (P<.001). Across the 2 experiments, the mean reduction was 24%.
Pooled genotyping revealed a trend for association between the lower-expression A allele of rs2070106 and schizophrenia (P = .06). Individual genotyping confirmed this finding at a level that meets conventional levels of significance (P = .04; odds ratio, 1.2 [95% confidence interval, 1.0-1.40]). Genotypic analysis revealed no stronger evidence (Table 1), nor did post hoc tests stipulating AA homozygotes as the risk genotype (P = .14; odds ratio, 1.3 [95% confidence interval 0.9-1.9]).
To look for evidence of a functional locus in LD with rs2070106, we performed a more detailed analysis of the CNP locus based on all the SNPs we previously detected supplemented by a grid of markers from databases at a minimum density of 1 SNP per 5 kb (Table 2). The optimal approach to LD mapping remains a subject of controversy, and therefore we applied 2 approaches. The first was to genotype all the earlier mentioned markers in pools on the premise that reduced df means that single-locus LD analysis based on a fairly dense set of markers may be more powerful than multilocus analysis if genotypes at 1 of the tested markers correlate strongly with those at the undetected locus. The second approach was based on haplotype analysis where our aim was to type a subset of the SNPs that could retrieve more than 95% of the haplotype diversity across the gene that would have been captured by genotyping all the earlier mentioned SNPs based on the entropy method (see the “Methods” section). This analysis revealed that by typing 3 markers (CNP −351, rs11296, and rs4796751) in addition to rs2070106, we could extract 98% of the haplotypic diversity that would be provided by genotyping all the markers. No additional evidence for association was obtained with any 2-, 3-, or 4-marker haplotype (data not shown). All genotypes were in Hardy-Weinberg equilibrium. The LD relationships between markers are given in Table 3.
To determine if variation at CNP was at least in part responsible for our previous report of linkage to 17q,11 we sequenced the exons of CNP in all 7 available family members. Additional sequence variants present in the family are presented in Table 2. None changed the predicted amino-acid sequence of the encoded CNP. Based on the microsatellite data,11 we had expected that all affected siblings would show identity by descent for both maternal and paternal chromosomes. Therefore, with respect to any 1 CNP marker, affected siblings would be either all homozygous or all heterozygous. However, for some markers (eg, rs4432296, CNP 4926, CNP 7230, and CNP 7284) homozygous and heterozygous affected subjects were observed, indicating that among the siblings, 3 parental chromosomes were represented with respect to the CNP locus. The availability of DNA allows us to determine that each affected subject received the same paternal copy of CNP, and therefore, we can conclude that for the CNP locus, both maternal chromosomes were represented in the affected siblings. Despite this, all the affected siblings in the family were homozygous for the minor lower-expression A allele at rs2070106. The prior probability that the single paternal chromosome transmitted would carry this allele is equal to the minor allele frequency (0.31) while that of the mother being homozygous for this allele is the square of the allele frequency (approximately 0.1). Conditional on the known pattern of chromosomal transmissions in this family, the prior probability that by chance both parents would have genotypes that would allow all affected siblings to be homozygous for the lower-expression allele is 0.03. If we do not allow for linkage (in our view, incorrectly), given the known parental genotypes (father heterozygous, mother uninformative homozygous), the corresponding probability is 0.56 = 0.015.
We also screened the whole 11 kb of CNP genomic sequence to look for further polymorphisms in our 14 unrelated patients with schizophrenia and the family 702 pedigree. This resulted in an additional 9 polymorphisms being detected in the CNP sequence. All were genotyped through the pooled-association sample, but none showed any evidence of association with schizophrenia (Table 2). The SNPs were also genotyped in 96 unrelated control subjects to calculate D′ and r2 values (Table 3).
Given previous reports of altered CNP expression in the schizophrenic brain, its location within a region to which we have previously reported linkage, and the observation of central nervous system pathological features in CNP-knockout mice reminiscent of findings reported in schizophrenia, we examined the specific hypothesis that sequence variants within CNP that influence its expression are associated with schizophrenia. Altered gene expression can be a consequence of cis- or trans-acting effects. For genetic analysis of a candidate gene, it is the former that is of relevance, and therefore, we first sought to confirm that CNP gene expression is in fact influenced by 1 or more cis-acting polymorphisms. Our allelic expression analysis clearly confirms the presence of such variants. The observation that in every sample, the A allele of marker rs2070106 is underexpressed compared with the G allele suggests that either the marker SNP itself is responsible for the altered expression or that by virtue of strong LD, haplotypes in which allele G is in phase with the lower-expression allele are uncommon.
Within the context of previous expression studies of the postmortem schizophrenic brain,2,3 our observation that allele A of rs2070106 is associated with lower CNP expression leads to a highly specific hypothesis, namely, that this locus is associated with schizophrenia. Moreover, unusual for candidate-gene studies, not only are we able to specify a specific SNP, our allelic expression data allow us to postulate a specific allele, namely that allele A is more common in affected individuals. Although only just meeting conventional criteria for significance, our findings in the case-control sample are entirely consistent with this hypothesis. Given the highly specific nature of the prior hypothesis with respect to both the SNP and the particular allele, we suggest that this very modest degree of support is stronger than a similar finding based on association with an anonymous SNP of no known functional relevance whose association is the end point of examination of multiple SNPs in and around a candidate gene.
To determine if variation at CNP was at least in part responsible for our previous report of linkage to 17q,11 we sequenced the exons of CNP in all family 702 pedigree members. This did not reveal any conspicuous sequence variants that might account for the linkage. Furthermore, the results showed that the CNP region on 17q had a lower level of identity by descent sharing than was previously predicted by our linkage study. Nevertheless, all of the affected siblings in the family were homozygous for the lower-expression A allele at marker rs2070106. Conditional on the genotypes and transmission patterns of the parental chromosomes, this observation can be expected to occur as an incidental finding around 3 times in 100 and provides fully independent support for CNP as a susceptibility gene for schizophrenia. However, we would also stress that, with a rate in the general population of around 10%, homozygosity for the putative susceptibility allele in CNP is not a highly penetrant recessive genotype and cannot alone account for our linkage finding in this family.
Further direct and indirect association analysis based on a dense map of markers, and, ultimately, on resequencing the full genomic sequence of CNP, revealed no further evidence for association between schizophrenia, either at the single marker or haplotype level. This suggests that if our finding is correct, marker rs2070106 is likely to be the susceptibility variant per se.
In conclusion, we have shown that CNP expression is under the influence of at least 1 cis-acting polymorphism. We have also shown that, consistent with previous findings of low CNP expression in the schizophrenic brain, an allele associated with lower CNP expression is also associated with schizophrenia. Our findings, while supported by a strong directional prior hypothesis and by observations in a family showing linkage to the region, are modest and certainly require independent replication. Nevertheless, they provide support for the specific hypothesis that reduced CNP expression in the schizophrenic brain may be etiologically relevant to schizophrenia. Moreover, given the context in which CNP is a functional candidate gene for schizophrenia, our data also provide support for the more general hypothesis that altered myelination and/or oligodendrocyte function may play a role in schizophrenia etiology.
Correspondence: Michael J. Owen, PhD, FRCPsych, Department of Psychological Medicine, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, Wales (email@example.com).
Submitted for Publication: December 10, 2004; final revision received May 5, 2005; accepted May 23, 2005.
Funding/Support: This work was funded by a component grant of a National Institute of Mental Health (Bethesda, Md)–funded Silvio O. Conte Centre for the Neuroscience of Mental Disorders coordinated by Kenneth Davis, MD, of Mount Sinai School of Medicine, New York, NY, and by grants from the Medical Research Council, London, England. Dr Moskvina is funded by a Higher Education Funding Council for Wales (Cardiff) initiative in biostatistics and bioinformatics.